Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|90|3|119-126

ISSN： 0030-2414

Source： Oncology, Vol.90, Iss.3, 2016-02, pp. : 119-126

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Progression‐free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

By  

CANCER, Vol. 120, Iss. 1, 2014-01 ,pp. : 52-60

John Wiley & Sons Inc

Access to resources Recommend Favorite

Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib

By  

Oncology, Vol. 89, Iss. 4, 2015-06 ,pp. : 235-241

Karger

Access to resources Recommend Favorite

An Open-Label Extension Study to Evaluate Safety and Efficacy of Pazopanib in Patients with Advanced Renal Cell Carcinoma

By  

Oncology, Vol. 87, Iss. 6, 2014-09 ,pp. : 342-350

Karger

Access to resources Recommend Favorite

Survival Trends among Patients with Advanced Renal Cell Carcinoma in the United States

By  

Urologia Internationalis, Vol. 94, Iss. 2, 2015-0 ,pp. : 133-136

Karger

Access to resources Recommend Favorite

Evaluation of disease‐free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial‐level meta‐analysis

By  

CANCER, Vol. 124, Iss. 5, 2018-03 ,pp. : 925-933

John Wiley & Sons Inc

Access to resources Recommend Favorite